These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 16115652

  • 1. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
    Gruszka A, Kunert-Radek J, Radek A, Pisarek H, Taylor J, Dong JZ, Culler MD, Pawlikowski M.
    Life Sci; 2006 Jan 11; 78(7):689-93. PubMed ID: 16115652
    [Abstract] [Full Text] [Related]

  • 2. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
    Pawlikowski M, Lawnicka H, Pisarek H, Kunert-Radek J, Radek M, Culler MD.
    J Physiol Pharmacol; 2007 Mar 11; 58(1):179-88. PubMed ID: 17440235
    [Abstract] [Full Text] [Related]

  • 3. [New medical treatments in pituitary adenomas].
    Drutel A, Caron P, Archambeaud F.
    Ann Endocrinol (Paris); 2008 Sep 11; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [Abstract] [Full Text] [Related]

  • 4. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
    Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, Scanarini M, Bondanelli M, Culler MD, degli Uberti EC.
    J Mol Endocrinol; 2005 Oct 11; 35(2):333-41. PubMed ID: 16216913
    [Abstract] [Full Text] [Related]

  • 5. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
    Hofland LJ, De Herder WW, Visser-Wisselaar HA, Van Uffelen C, Waaijers M, Zuyderwijk J, Uitterlinden P, Kros MJ, Van Koetsveld PM, Lamberts SW.
    J Clin Endocrinol Metab; 1997 Sep 11; 82(9):3011-8. PubMed ID: 9284735
    [Abstract] [Full Text] [Related]

  • 6. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, Venegas-Moreno E, de la Riva A, Arráez MÁ, González-Molero I, Schmid HA, Maraver-Selfa S, Gavilán-Villarejo I, García-Arnés JA, Japón MA, Soto-Moreno A, Gálvez MA, Luque RM, Castaño JP.
    J Endocrinol; 2016 Nov 11; 231(2):135-145. PubMed ID: 27587848
    [Abstract] [Full Text] [Related]

  • 7. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A, Jaquet P, Brue T, Barlier A.
    Mol Cell Endocrinol; 2008 May 14; 286(1-2):206-13. PubMed ID: 18241980
    [Abstract] [Full Text] [Related]

  • 8. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P.
    Neuroendocrinology; 2006 May 14; 83(3-4):258-63. PubMed ID: 17047391
    [Abstract] [Full Text] [Related]

  • 9. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.
    Ibáñez-Costa A, López-Sánchez LM, Gahete MD, Rivero-Cortés E, Vázquez-Borrego MC, Gálvez MA, de la Riva A, Venegas-Moreno E, Jiménez-Reina L, Moreno-Carazo A, Tinahones FJ, Maraver-Selfa S, Japón MA, García-Arnés JA, Soto-Moreno A, Webb SM, Kineman RD, Culler MD, Castaño JP, Luque RM.
    Sci Rep; 2017 Feb 09; 7():42002. PubMed ID: 28181484
    [Abstract] [Full Text] [Related]

  • 10. A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas.
    Körner M, Waser B, Christ E, Beck J, Reubi JC.
    Neuroendocrinology; 2018 Feb 09; 106(2):116-127. PubMed ID: 28384628
    [Abstract] [Full Text] [Related]

  • 11. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
    Gatto F, Barbieri F, Gatti M, Wurth R, Schulz S, Ravetti JL, Zona G, Culler MD, Saveanu A, Giusti M, Minuto F, Hofland LJ, Ferone D, Florio T.
    Clin Endocrinol (Oxf); 2012 Mar 09; 76(3):407-14. PubMed ID: 21848909
    [Abstract] [Full Text] [Related]

  • 12. Effects of somatostatin on vascular endothelial growth factor (VEGF) secretion from non-functioning pituitary tumoral cells incubated in vitro.
    Ławnicka H, Pisarek H, Kunert-Radek J, Pawlikowski M.
    Neuro Endocrinol Lett; 2008 Feb 09; 29(1):113-6. PubMed ID: 18283262
    [Abstract] [Full Text] [Related]

  • 13. Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro.
    Gruszka A, Culler MD, Melmed S.
    Mol Cell Endocrinol; 2012 Oct 15; 362(1-2):104-9. PubMed ID: 22705877
    [Abstract] [Full Text] [Related]

  • 14. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.
    Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2002 Dec 15; 87(12):5545-52. PubMed ID: 12466351
    [Abstract] [Full Text] [Related]

  • 15. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
    Schaer JC, Waser B, Mengod G, Reubi JC.
    Int J Cancer; 1997 Mar 04; 70(5):530-7. PubMed ID: 9052751
    [Abstract] [Full Text] [Related]

  • 16. Immunohistochemical detection of somatostatin receptor subtypes in "clinically nonfunctioning" pituitary adenomas.
    Pawlikowski M, Pisarek H, Kunert-Radek J, Radek A.
    Endocr Pathol; 2003 Mar 04; 14(3):231-8. PubMed ID: 14586068
    [Abstract] [Full Text] [Related]

  • 17. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
    Padova H, Rubinfeld H, Hadani M, Cohen ZR, Nass D, Taylor JE, Culler MD, Shimon I.
    Mol Cell Endocrinol; 2008 May 14; 286(1-2):214-8. PubMed ID: 18276067
    [Abstract] [Full Text] [Related]

  • 18. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.
    Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD, Melmed S.
    J Clin Endocrinol Metab; 2003 Nov 14; 88(11):5414-21. PubMed ID: 14602782
    [Abstract] [Full Text] [Related]

  • 19. Genetic abnormalities of somatostatin receptors in pituitary tumors.
    Lania A, Mantovani G, Spada A.
    Mol Cell Endocrinol; 2008 May 14; 286(1-2):180-6. PubMed ID: 17913341
    [Abstract] [Full Text] [Related]

  • 20. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
    Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, Dousset B, Bertagna X, Epelbaum J.
    J Clin Endocrinol Metab; 2003 Nov 14; 88(11):5353-60. PubMed ID: 14602773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.